Clinical Trial

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2a randomised, placebo controlled, double-blind study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALE1 on healthy adult subjects and adult patients with Hypophosphatasia (HPP).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-16; most recent amendment 2026-01-28.
Status change: Not Yet Recruiting → Recruiting 2025-11-24
Trial Details
NCT Number NCT07179640
Lead Sponsor Alesta Therapeutics
Conditions Hypophosphatasia (HPP)
Enrollment 120 participants
Start Date 2025-09-30
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-03